Craft

Advanced
  • Home
  •  / Lexeo Therapeutics
Lexeo Therapeutics

Lexeo Therapeutics

Stock Price

$10

2024-10-29

Market Capitalization

$329.6 M

2024-10-29

Lexeo Therapeutics Summary

Company Summary

Overview
Lexeo Therapeutics is a company that specializes in genetic medicines. It focuses on genetically defined cardiovascular diseases and APOE4-associated Alzheimer’s disease.
Type
Public
Status
Active
Founded
2018
HQ
New York, NY, US | view all locations
Website
https://www.lexeotx.com/
Cybersecurity rating
Sectors

Table of Contents

Key People

  • R. Nolan Townsend

    R. Nolan Townsend, Chief Executive Officer

    • Eric Adler

      Eric Adler, Chief Scientific Officer

      • Paul McCormac

        Paul McCormac, Chief Technical Officer

        • Jenny Robertson

          Jenny Robertson, Chief Legal and Administrative Officer

          LocationsView all

          1 location detected

          • New York, NY HQ

            United States

            345 Park Ave S #6

          Lexeo Therapeutics Financials

          Summary Financials

          Net income (Q1, 2026)
          ($20.2M)
          Cash (Q1, 2026)
          $71.8M
          EBIT (Q1, 2026)
          ($22.3M)
          Enterprise value
          $264.7M

          Competitors and Similar Companies

          Compare competitors

          Footer menu

          Product

          Solutions

          Resources

          Company

          © Craft.co 2026
          Share price data provided by IEX